A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

Phase 2 Terminated 562 enrolled Boehringer Ingelheim

RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluation of safety and efficacy of Tipranavir (TPV) boosted with Ritonavir (RTV) versus an active control arm (Lopinavir / RTV) in antiretroviral (ARV) therapy naïve HIV-1 infected patients

Timeline

Start: 2004-02
Primary completion: 2006-11
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LPV400mg/RTV100mgBID	Unknown	400 mg	—
Subject	Ritonavir	Other / unclassified	100 mg	Oral
Subject	Ritonavir	Other / unclassified	200 mg	Oral
Subject	Tipranavir	Small molecule	500 mg	Oral

A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

Summary

Timeline

Drugs

Indications